Therefore, in the present study, we conducted an updated systematic review and meta-analysis to clarify the association of CYP2C19 genotype with efficacy and safety of clopidogrel-based antiplatelet therapy in non-East Asian patients with stroke or TIA. The gene discussed is CYP2C19; the disease is transient ischemic attack.